Jefferies Financial Group initiated coverage on shares of Commonwealth Bank of Australia (OTCMKTS:CSLLY) in a report released on Monday morning, The Fly reports. The brokerage issued a buy rating on the stock.
Other equities research analysts have also issued research reports about the stock. ValuEngine lowered shares of Commonwealth Bank of Australia from a hold rating to a sell rating in a report on Wednesday, October 2nd. Zacks Investment Research lowered shares of Commonwealth Bank of Australia from a hold rating to a sell rating in a report on Monday, October 14th.
Shares of OTCMKTS:CSLLY traded up $0.40 on Monday, reaching $86.45. The company’s stock had a trading volume of 68,041 shares, compared to its average volume of 28,917. Commonwealth Bank of Australia has a 52-week low of $60.89 and a 52-week high of $86.89. The business has a 50-day moving average price of $81.33. The company has a market cap of $77.95 billion, a P/E ratio of 40.78 and a beta of 0.65. The company has a current ratio of 2.53, a quick ratio of 1.14 and a debt-to-equity ratio of 0.81.
Commonwealth Bank of Australia Company Profile
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
Featured Article: What causes a stock to be most active?
Receive News & Ratings for Commonwealth Bank of Australia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Commonwealth Bank of Australia and related companies with MarketBeat.com's FREE daily email newsletter.